The stock of Patheon NV (NYSE:PTHN) is a huge mover today! About 413,049 shares traded hands or 24.29% up from the average. Patheon NV (NYSE:PTHN) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.
The move comes after 7 months positive chart setup for the $4.07 billion company. It was reported on Nov, 29 by Barchart.com. We have $29.12 PT which if reached, will make NYSE:PTHN worth $162.80 million more.
Patheon NV (NYSE:PTHN) Ratings Coverage
Out of 12 analysts covering Patheon (NYSE:PTHN), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Patheon has been the topic of 14 analyst reports since August 15, 2016 according to StockzIntelligence Inc. The company was initiated on Monday, August 15 by UBS. The firm has “Overweight” rating by KeyBanc Capital Markets given on Monday, August 15. The rating was initiated by Piperjaffray on Monday, August 15 with “Overweight”. The rating was initiated by Wells Fargo with “Outperform” on Monday, August 15. The firm earned “Buy” rating on Tuesday, August 16 by Evercore. Robert W. Baird initiated Patheon NV (NYSE:PTHN) rating on Monday, August 15. Robert W. Baird has “Outperform” rating and $32 price target. The rating was initiated by Jefferies on Tuesday, August 16 with “Buy”. The firm has “Outperform” rating by William Blair given on Monday, August 15. The rating was initiated by PiperJaffray with “Overweight” on Monday, August 15. Morgan Stanley initiated the shares of PTHN in a report on Monday, August 15 with “Overweight” rating.
According to Zacks Investment Research, “Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands.”
More notable recent Patheon NV (NYSE:PTHN) news were published by: Streetinsider.com which released: “Patheon N.V. (PTHN) to Acquire API Manufacturing Site in South Carolina” on November 28, 2016, also Reuters.com with their article: “BRIEF-Patheon NV will acquire site for an immaterial sum, plus cost of ass…” published on November 28, 2016, Marketwatch.com published: “Patheon started at buy at Evercore ISI” on June 09, 2015. More interesting news about Patheon NV (NYSE:PTHN) were released by: Reuters.com and their article: “BRIEF-Patheon NV says three of its manufacturing sites experienced tempora…” published on October 14, 2016 as well as Seekingalpha.com‘s news article titled: “IPO Quiet Period Expiration: Patheon N.V.” with publication date: August 10, 2016.
PTHN Company Profile
Patheon NV, formerly Patheon Holdings Cooperatief U.A., is engaged in providing outsourced pharmaceutical development and manufacturing (CDMO) services. The Firm provides a range of active pharmaceutical ingredient (API) and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and lifecycle management. The Company’s services address both small molecule and large molecule biological drugs. Through the Company’s Patheon OneSource, provide its clients with solutions for both small molecule and large molecule biological pharmaceuticals across its three divisions, including development and manufacturing services for API (Drug Substance Services, or DSS), formulation development and pre-clinical and clinical drug product manufacturing (Pharmaceutical Development Services, or PDS) and commercial drug product manufacturing and packaging (Drug Product Services, or DPS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.